Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.
Sep 2011 - Head Neck; 33(10):1097-0347 [PMID:21928411]
[Li P] [Chen CH] [Li S] [Givi B] [Yu Z] [Zamarin D] [Palese P] [Fong Y] [Wong RJ]

Oncolytic specificity of newcastle disease virus is mediated by selectivity for apoptosis-resistant cells.
May 2011 - J. Virol.; 85(12):1098-5514 [PMID:21471241]
[Mansour M] [Palese P] [Zamarin D]

Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer.
Nov 2010 - Head Neck:1097-0347 [PMID:21053297]
[Li P] [Chen CH] [Li S] [Givi B] [Yu Z] [Zamarin D] [Palese P] [Fong Y] [Wong RJ]

Genetically Engineered Oncolytic Newcastle Disease Virus Effectively Induces Sustained Remission of Malignant Pleural Mesothelioma.
Sep 2010 - :1538-8514 [PMID:20858727]
[Silberhumer GR] [Brader P] [Wong J] [Serganova IS] [Gönen M] [Gonzalez SJ] [Blasberg R] [Zamarin D] [Fong Y]

Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer.
Apr 2010 - :1432-1440 [PMID:20393691]
[Song KY] [Wong J] [Gonzalez L] [Sheng G] [Zamarin D] [Fong Y]

Genetically engineered Newcastle disease virus for malignant melanoma therapy.
Jun 2009 - Gene Ther.; 16(6):1476-5462 [PMID:19242529]
[Zamarin D] [Vigil A] [Kelly K] [García-Sastre A] [Fong Y]

Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses.
Apr 2009 - Mol. Ther.; 17(4):1525-0024 [PMID:19209145]
[Zamarin D] [Martínez-Sobrido L] [Kelly K] [Mansour M] [Sheng G] [Vigil A] [García-Sastre A] [Palese P] [Fong Y]